Anne Schuind

Medicine · Health Sciences

33h-index7.2kcitations105works10.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Herpesvirus Infections and Treatments(32), Influenza Virus Research Studies(29), Hepatitis B Virus Studies(27), Cervical Cancer and HPV Research(26), Respiratory viral infections research(16)

Publications103 total

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
The Lancet Infectious Diseases·2025· 6 citedOpen Access
Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy
JNCI Monographs·2024· 10 citedOpen Access
Evidence for an HPV one-dose schedule
Vaccine·2024· 16 citedOpen Access
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial
Vaccine·2024· 22 citedOpen Access
Immunogenicity and Safety of Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine in Girls 9–14 Years of Age in Low- and Middle-Income Countries: Final Data of Randomized Controlled Trial
SSRN Electronic Journal·2024Open Access
Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study
BMC Health Services Research·2023· 11 citedOpen Access
REPRINTED WITH PERMISSION OF IASP PAIN 164 (2023) 741748: Adjuvanted recombinant zoster vaccine decreases herpeszoster-associated pain and the use of pain medicationacross 3 randomized, placebo-controlled trials
Ból·2023
State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop
Preventive Medicine Reports·2023· 8 citedOpen Access
Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling Study
Vaccines·2023· 14 citedOpen Access
Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study
Vaccine·2023· 23 citedOpen Access
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
Pain·2022· 14 citedOpen Access
Human Papilloma-Virus Associated Carcinomas and Warts
2021
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction–Confirmed Influenza Illness in Children 6–35 Months of Age: Statistical Evaluation of a Correlate of Protection
Open Forum Infectious Diseases·2021· 8 citedOpen Access
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Human Vaccines & Immunotherapeutics·2021· 33 citedOpen Access
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Clinical Infectious Diseases·2021· 90 citedOpen Access
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age
The Pediatric Infectious Disease Journal·2021· 12 citedOpen Access
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
Human Vaccines & Immunotherapeutics·2021· 17 citedOpen Access
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
Drug Safety·2021· 30 citedOpen Access
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
Human Vaccines & Immunotherapeutics·2021· 16 citedOpen Access
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
Vaccine·2020· 16 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Toufik Zahaf(10), Bruce L. Innis(9), Gary Dubin(8), Scott A. Halperin(8), Cosette M. Wheeler(7), Paulo Naud(7), Cecília Roteli-Martins(7), Diane M. Harper(6), Eduardo L. Franco(6), Júlio César Teixeira(6), Mark M. Blatter(6), Barbara Romanowski(6), Myron J. Levin(6), Lidia Oostvogels(6), Jane Gidudu(6), Paul T. Heath(6), Renald Hennig(6), Frederick Varricchio(6), David Jenkins(5), Newton Sérgio de Carvalho(5)